Neuromodulation has the capacity to address acute and chronic effects of COVID-19
The ICNC was established in early 2020 in response to the SARS-CoV-2 pandemic, and the realization that many critically ill patients suffering from COVID-19, the disease caused by the novel coronavirus, were experiencing systemic hyperinflammation, organ failure, shock, and death.
ICNC Founding Members
MAROM BIKSON, PhD
Professor, Biomedical Engineering
The City College of New York
JIANDE CHEN, PhD
Professor of Medicine
Director, Neuromodulation
University of Michigan School of Medicine
CHRIS CZURA, PhD
Co-Founder and Chief Scientist
Convergent Medical Technologies, Inc.
MANFRED FRANKE, PhD
CEO, Founder
Neuronoff, Inc.
ERIC GRIGSBY, MD, MBA
President and CEO
Neurovations
SAMUEL HAMNER, PhD
Director of Product Innovation
Cala Health
JARED HUSTON, MD, FACS
Associate Professor of Surgery
Feinstein Institutes for Medical Research
Zucker School of Medicine
NAVID KHODAPARAST, PhD
Chief Science Officer
Spark Biomedical, Inc.
ELLIOT KRAMES, MD
Founding Editor in Chief,
Neuromodulation
Past President, International Neuromodulation Society
YAAKOV LEVINE, PhD
Director, Applied Research
SetPoint Medical
PEDER OLOFSSON, MD, PhD
Founding Director
Center for Bioelectronic Medicine, Department of Medicine, Karolinska Institutet
LAWRENCE POREE, MD, PhD
Director, Neuromodulation Service, Division of Pain Medicine
University of California, San Francisco
PETER STAATS, MD, PhD
Co-founder and CMO, electroCore
CMO, National Spine and Pain Centers
President-elect, World Institute of Pain
KRISTL VONCK, MD, PhD
Associate Professor of Neurology
Ghent University, Belgium
General Partners
JOJO PLATT
President,
Platt & Associates, Inc.
DANIEL POWELL, BBA
CEO
Spark Biomedical, Inc.